Page 1 | Search Results | Blood Advances | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-2 of 2

Sort by

Sort Order Select

Journal Articles

Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML

Anna B. Halpern, Eduardo Rodríguez-Arbolí, Megan Othus, Kelsey-Leigh A. Garcia, Mary-Elizabeth M. Percival, Ryan D. Cassaday, Vivian G. Oehler, Pamela S. Becker, Jacob S. Appelbaum, Janis L. Abkowitz, Johnnie J. Orozco, Siobán B. Keel, Paul C. Hendrie, Bart L. Scott, M. Cristina Ghiuzeli, Elihu H. Estey, Roland B. Walter

Blood Adv (2023) 7 (17): 4950–4961.

https://doi.org/10.1182/bloodadvances.2023010392

Published: 2023

Journal Articles

Megadose 90 Y-ibritumomab tiuxetan prior to allogeneic transplantation is effective for aggressive large B-cell lymphoma

Victor A. Chow, Ryan D. Cassaday, Theodore A. Gooley, Stephen D. Smith, Brenda M. Sandmaier, Damian J. Green, Johnnie J. Orozco, Sherilyn A. Tuazon, Manuela Matesan, Darrell R. Fisher, David G. Maloney, Oliver W. Press, Ajay K. Gopal

Blood Adv (2021) 6 (1): 37–45.

https://doi.org/10.1182/bloodadvances.2021005056

Published: 2021